Related news from
Fri, 07 Aug 2026 20:44:57 +0000	AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
Fri, 07 Aug 2026 18:20:00 +0000	Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results? Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Thu, 06 Aug 2026 11:04:13 +0000	Cencora Q3 Earnings Call Highlights Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook. Adjusted operating
Thu, 06 Aug 2026 03:04:18 +0000	Cencora, Inc. Q3 2026 Earnings Call Summary Moby summary of Cencora, Inc.'s Q3 2026 earnings call
Wed, 05 Aug 2026 21:06:10 +0000	Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance Cencora Inc (COR) delivered 17% adjusted operating income growth and raised its full-year EPS outlook, driven by robust specialty performance and strategic share repurchases.
Wed, 05 Aug 2026 17:11:06 +0000	Cencora (COR) Expands Credit Facilities And Resets Receivables Terms Cencora (NYSE:COR) has amended its credit and receivables facilities, including changes to its multi currency revolving credit facility and receivables securitization arrangements. The company has adjusted the size and maturity profile of its revolving credit facility and updated terms related to its receivables securitization structure. These financing changes are recent and represent material developments for Cencora’s capital structure and liquidity toolkit. Cencora operates as a major...
Wed, 05 Aug 2026 14:50:00 +0000	COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.
Wed, 05 Aug 2026 13:30:03 +0000	Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wed, 05 Aug 2026 12:56:16 +0000	Cencora raises full-year guidance after stronger-than-expected third-quarter results Cencora (NYSE:COR) reported third-quarter results that exceeded Wall Street expectations, prompting the pharmaceutical services company to raise its full-year earnings guidance. The stronger performance helped lift the shares more than 3% in pre-market trading.
Wed, 05 Aug 2026 11:45:03 +0000	Cencora (COR) Surpasses Q3 Earnings Estimates Cencora (COR) delivered earnings and revenue surprises of +2.52% and -0.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Wed, 05 Aug 2026 10:43:59 +0000	Cencora’s (NYSE:COR) Q2 CY2026 Earnings Results: Revenue In Line With Expectations Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAAP profit of $4.48 per share was 3% above analysts’ consensus estimates.
Wed, 05 Aug 2026 10:30:00 +0000	Cencora Reports Fiscal 2026 Third Quarter Results CONSHOHOCKEN, Pa., August 05, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, incr
Tue, 04 Aug 2026 19:08:00 +0000	What's in Store for These 4 Healthcare Companies This Earnings Season? McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Tue, 04 Aug 2026 16:22:00 +0000	DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock? XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Mon, 03 Aug 2026 18:57:00 +0000	Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock? COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.
Mon, 03 Aug 2026 18:55:00 +0000	Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results? McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.
Mon, 03 Aug 2026 16:36:00 +0000	Solventum to Report Q2 Earnings: What's in Store for the Stock? SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
Fri, 31 Jul 2026 17:24:00 +0000	GMED's Q2 Earnings on Deck: Will Enabling Technologies Lead Results? Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.
Fri, 31 Jul 2026 15:30:23 +0000	Cencora (COR) Remains Attractive Despite Temporary Headwinds Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% and slightly outperforming the Russell Midcap® Value Index’s 13.40% gain. Information […]
Fri, 31 Jul 2026 13:15:02 +0000	Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!